<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01668706</url>
  </required_header>
  <id_info>
    <org_study_id>MD098SCW01</org_study_id>
    <nct_id>NCT01668706</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts</brief_title>
  <official_title>Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid abuse is a complex problem, which not only impacts on addicts' physical and&#xD;
      psychological health individually, but also threats the society. Recently, spread of HIV via&#xD;
      sexual behavior and needle sharing among injecting drug users (IDUs) also becomes a serious&#xD;
      public health problem all over the world. In Taiwan, since the first HIV-infected IDU&#xD;
      identified in 1987, the incident cases have mounted to 2,461 in 2005. To prevent the&#xD;
      epidemics of HIV among IDUs, the Center for Disease Control (CDC) thus collaborated with&#xD;
      Department of Justice and implemented harm reduction programs in 2005. It is the milestone&#xD;
      that opioid addiction is officially treated as a health rather than a legal issue in Taiwan.&#xD;
      Among the harm reduction programs of needle and syringe exchange for IDUs as well as&#xD;
      substitution treatment for opioid dependence, methadone maintenance treatment (MMT) is one of&#xD;
      the most important parts. Till 2008, there were over 13,000 heroin addicts participated in&#xD;
      more than 80 MMT programs.&#xD;
&#xD;
      Although the clinical evidences have proven the superior effectiveness of maintenance therapy&#xD;
      in ameliorating illicit substances abuse, decreasing criminality and improving quality of&#xD;
      life, there are common problems of sleep disturbance and neurocognitive impairments among the&#xD;
      subjects receiving opioid medications. The concerns of the adverse effects might thus&#xD;
      frustrate the subjects' motivation and compliance to maintain treatments. However, sleep&#xD;
      disturbance and neurocognitive impairments related to opioid medications are often neglected&#xD;
      in the clinical practices and there are scanty researches focusing on these crucial issues in&#xD;
      the existing literature.&#xD;
&#xD;
      In this prospective study, four groups of subjects including methadone maintenance treatment,&#xD;
      buprenorphine/naloxone, medication-free opioid ex-addicts and healthy volunteers will be&#xD;
      enrolled. Via the comprehensive assessments including clinical interview, neurocognitive&#xD;
      examinations, electrocardiogram-based sleep breathing detector and pharmacogenomical&#xD;
      evaluation, we will not only have the opportunities to have more insights on the impacts of&#xD;
      opioid medications on sleep and neurocognitive performances, but also develop more adequate&#xD;
      strategies to improve motivation and outcome in treating the opioid addicts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Group differences in demopraphics</measure>
    <time_frame>one year</time_frame>
    <description>support system, vital sign, substance use history</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gruop differences in neuro-cognitive functions</measure>
    <time_frame>one year</time_frame>
    <description>attention, executive function, decision making</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">340</enrollment>
  <condition>Heroin Dependence</condition>
  <arm_group>
    <arm_group_label>Methadone maintenance treatment (MMT)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine-Naloxone treatment (BNT)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Medication-free ex-addicts(MF)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal control (NC)</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, DNA and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Normal control group:&#xD;
&#xD;
             Healthy adults will be recruited from community.&#xD;
&#xD;
          2. Methadone Maintenance treatment group Study subjects will be enrolled only in the&#xD;
             methadone clinic.&#xD;
&#xD;
          3. Buprenorphine/Naloxone treatment group Subjects will be enrolled only in the clinic.&#xD;
&#xD;
          4. Drug-free ex-addict group Subjects will be recruited from the therapeutic communities&#xD;
             and halfway house of Operation Dawn.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Normal control group (NC):&#xD;
&#xD;
             Inclusion criteria:&#xD;
&#xD;
               1. Chinese ethnicity&#xD;
&#xD;
               2. Men or women above age of 20&#xD;
&#xD;
               3. Able to participate in a clinical assessment in Chinese (including Mandarin and&#xD;
                  Taiwanese dialects)&#xD;
&#xD;
               4. Individuals who have completed a written consent form&#xD;
&#xD;
             Exclusion criteria:&#xD;
&#xD;
               1. Patients with comorbid severe mental disorders including:&#xD;
&#xD;
                    1. Organic mental disorders, or&#xD;
&#xD;
                    2. Schizophrenia&#xD;
&#xD;
               2. Past diagnosis of Heroin dependence by DSM-IV definition&#xD;
&#xD;
               3. Severe cognitive impairment&#xD;
&#xD;
               4. Being pregnant&#xD;
&#xD;
          2. Methadone maintenance treatment group (MMT)&#xD;
&#xD;
             Inclusion criteria:&#xD;
&#xD;
               1. Chinese ethnicity&#xD;
&#xD;
               2. Men or women above age of 20, below age of 65&#xD;
&#xD;
               3. Able to participate in a clinical assessment in Chinese (including Mandarin and&#xD;
                  Taiwanese dialects)&#xD;
&#xD;
               4. Diagnosis of Heroin dependence by DSM-IV definition&#xD;
&#xD;
               5. Enter methadone maintenance therapy for at least 3 months&#xD;
&#xD;
               6. No change of methadone dosage for the last week&#xD;
&#xD;
               7. Regularly took methadone for the last week&#xD;
&#xD;
               8. Individuals who have completed a written consent form&#xD;
&#xD;
             Exclusion criteria:&#xD;
&#xD;
               1. Patients with comorbid severe mental disorders including:&#xD;
&#xD;
                    1. Organic mental disorders, or&#xD;
&#xD;
                    2. Schizophrenia&#xD;
&#xD;
               2. Severe cognitive impairment&#xD;
&#xD;
               3. Being pregnant&#xD;
&#xD;
          3. Buprenorphine/Naloxone treatment group (BNT)&#xD;
&#xD;
             Inclusion criteria:&#xD;
&#xD;
               1. Chinese ethnicity&#xD;
&#xD;
               2. Men or women above age of 20, below age of 65&#xD;
&#xD;
               3. Able to participate in a clinical assessment in Chinese (including Mandarin and&#xD;
                  Taiwanese dialects)&#xD;
&#xD;
               4. Diagnosis of Heroin dependence by DSM-IV definition&#xD;
&#xD;
               5. Enter buprenorphine maintenance therapy for at least 3 months&#xD;
&#xD;
               6. No change of buprenorphine dosage for the last week&#xD;
&#xD;
               7. Regularly took buprenorphine for the last week&#xD;
&#xD;
               8. Individuals who have completed a written consent form&#xD;
&#xD;
             Exclusion criteria:&#xD;
&#xD;
               1. Patients with comorbid severe mental disorders including:&#xD;
&#xD;
                    1. Organic mental disorders, or&#xD;
&#xD;
                    2. Schizophrenia&#xD;
&#xD;
               2. Severe cognitive impairment&#xD;
&#xD;
               3. Being pregnant&#xD;
&#xD;
          4. Medication-free ex-addict group (MF)&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          1. Chinese ethnicity&#xD;
&#xD;
          2. Men or women above age of 20&#xD;
&#xD;
          3. Able to participate in a clinical assessment in Chinese (including Mandarin and&#xD;
             Taiwanese dialects)&#xD;
&#xD;
          4. Diagnosis of Heroin dependence by DSM-IV definition&#xD;
&#xD;
          5. Individuals who have completed a written consent form&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patients with comorbid severe mental disorders including:&#xD;
&#xD;
               1. Organic mental disorders, or&#xD;
&#xD;
               2. Schizophrenia&#xD;
&#xD;
          2. Severe cognitive impairment&#xD;
&#xD;
          3. Being pregnant&#xD;
&#xD;
          4. Exposure of methadone, buprenorphine and other opioid treatment in the previous 3&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheng-Chang Wang, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Research Institutes, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ChangHua Christian Hospital</name>
      <address>
        <city>Lukang</city>
        <state>ChangHua</state>
        <zip>50550</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Banqiao</city>
        <state>New Taipei City</state>
        <zip>22060</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Banqiao</city>
        <state>New Taipei</state>
        <zip>22060</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>En-Chu-Gong Hospital</name>
      <address>
        <city>Sanxia</city>
        <state>New Taipei</state>
        <zip>23702</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Research Institute</name>
      <address>
        <city>Miaoli County</city>
        <zip>35053</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>August 16, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2012</study_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

